JV
Therapeutic Areas
X4 Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| XOLREMDI (mavorixafor) | WHIM Syndrome | Approved |
| Mavorixafor | Chronic Neutropenic Disorders | Phase 3 |
Leadership Team at X4 Pharmaceuticals
AC
Adam Craig, MD, PhD, MBA
Executive Chair
DK
David Kirske
Chief Financial Officer
GJ
Gary J. Bridger, PhD
Board Member